Arrowhead Pharmaceuticals Inc. (ARWR)

28.52
0.36 1.28
NASDAQ : Health Technology
Prev Close 28.16
Open 28.44
Day Low/High 27.94 / 28.74
52 Wk Low/High 10.41 / 28.84
Volume 828.98K
Avg Volume 2.01M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.64B
EPS -0.70
P/E Ratio 397.14
Div & Yield N.A. (N.A)
Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under clinical investigation for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25 th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016 ...

Relative Strength Alert For Arrowhead Pharmaceuticals

Relative Strength Alert For Arrowhead Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver Meeting®

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company's investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin...

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Amgen (AMGN) is partnering with Arrowhead Pharmaceuticals (ARWR) to develop two cardiovascular disease treatments using its RNAi therapy.

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver disease associated with alpha-1...

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Notable Thursday Option Activity: ARWR, ROST, OUTR

Notable Thursday Option Activity: ARWR, ROST, OUTR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc , where a total of 3,324 contracts have traded so far, representing approximately 332,400 underlying shares. That amounts to about 61.7% of ARWR's average daily trading volume over the past month of 538,710 shares.

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW...

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Reports Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016.

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has priced a private offering of its common stock with gross proceeds expected to be $45 million.

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Third Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Commit To Purchase Arrowhead Pharmaceuticals At $3, Earn 15% Using Options

Investors eyeing a purchase of Arrowhead Pharmaceuticals Inc shares, but cautious about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 45 cents.

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single And Multiple Dose Study Of Hepatitis B Candidate ARC-521

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Reports Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016.

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown And Long Duration Of Effect After Subcutaneous Administration

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the...

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals To Webcast Fiscal 2016 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.

Arrowhead Pharmaceuticals To Present At Upcoming May Conferences

Arrowhead Pharmaceuticals To Present At Upcoming May Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARC-521

Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARC-521

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic...

First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of December 16th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals Presents Preclinical Data On Renal Cell Carcinoma Program At AACR 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-a for the treatment of renal cell carcinoma (RCC), at the American Association for...

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Here’s Why Arrowhead Pharma (ARWR) Stock Closed Up Today

Arrowhead Pharma (ARWR) stock continued to climb on Thursday after the release of ‘promising’ data about its lead product candidate for the treatment of the hepatitis B infection yesterday.

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data

Arrowhead Pharma (ARWR) stock are rising following the release of encouraging data about the company's lead product candidate for the treatment of the hepatitis B virus infection.

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data At The International Liver Congress™ 2016

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver...

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Changes Name To Arrowhead Pharmaceuticals

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc.

TheStreet Quant Rating: C+ (Hold)